Tirzepatide for Obstructive Sleep Apnea: The SURMOUNT-OSA Trial
High Confidence RCT Linked compounds: tirzepatide
Outcomes summary
Phase 3 randomized trial evaluating tirzepatide versus placebo in adults with obesity and moderate-to-severe obstructive sleep apnea; tirzepatide demonstrated statistically significant and clinically meaningful improvement in apnea-hypopnea index (AHI) and sleep-related outcomes, along with substantial weight reduction in the studied population.
Limitations
Trial duration and population may limit generalizability; results depend on dose-escalation and adherence; longer-term safety and hard outcomes require additional evidence; specific AHI reduction thresholds and durability of effects after treatment discontinuation need further study.
Notes
Primary source: SURMOUNT-OSA (2024).